• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Allergan

AbbVie gains U.S. nod for $63B Allergan takeover

May 6, 2020 By Nancy Crotti

Pharmaceutical giant  AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its  purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. Federal Trade Commission […]

Filed Under: Business/Financial News, Featured, Immunotherapy, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Allergan, AstraZeneca plc, Federal Trade Commission (FTC), Johnson & Johnson

FDA approves expanded indication for Liletta 6-year IUD

October 28, 2019 By Sean Whooley

Allergan, Medicines360

Medicines360 and its partner Allergan (NYSE:AGN) said today that the FDA approved Medicines360’s supplemental new drug application to extend the duration use of the Liletta intrauterine device for up to six years. The Liletta levonorgestrel-releasing intrauterine system now has the longest approved duration of use for a hormonal intrauterine device in the U.S., according to a […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Women's Health Tagged With: Allergan, FDA, Medicines360

AbbVie to buy Allergan for $63 billion

June 25, 2019 By Nancy Crotti

Pharmaceutical giant AbbVie (NYSE:ABBV) said today it will acquire Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. AbbVie will pay Allergan shareholders $188.24 per share of Allergan stock, a 45% premium to yesterday’s closing price. Humira […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Uncategorized, Wall Street Beat Tagged With: AbbVie, Allergan

Report: Pharma companies kick off new year with price hikes

January 2, 2019 By Sarah Faulkner

Prescription drugs

Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Allergan (NYSE:AGN) topped the list, raising the […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Biogen, Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer Inc.

FDA approves five-year hormonal contraceptive

October 16, 2018 By Sarah Faulkner

Allergan, Medicines360

Allergan (NYSE:AGN) and the nonprofit women’s health pharma company Medicines360 said today that the FDA approved an application to extend the duration of use for Liletta for the prevention of pregnancy for up to five years. Medicines360 first won approval for the levonorgestrel-releasing intrauterine device in February of 2015. The system’s latest FDA approval is based on a […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Allergan, Medicines360

Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique

July 12, 2018 By Sarah Faulkner

Oyster Point Pharma logo

Large pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops. Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach. “What we’ve come up with is a very innovative nasal spray, which when […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Allergan, oysterpointpharma

Tribe taking steps to ‘ramp up’ drug patent business

May 22, 2018 By Sarah Faulkner

gavel

The Native American tribe wrapped up in litigation with generic pharmaceutical companies is trying to prove that its arrangement with Allergan (NYSE:AGN) reflects a legitimate move to boost its economy, according to court documents. The St. Regis Mohawk Tribe of New York found itself it the middle of a controversial deal this year after it agreed […]

Filed Under: Featured, Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Mylan

Allergan touts 5-year data for Liletta intrauterine contraceptive

May 1, 2018 By Sarah Faulkner

Allergan, Medicines360

Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta. The levonorgestrel-releasing contraceptive is approved in the U.S. to be used to prevent pregnancy for up to four years. The companies collected data from women who ranged from 16 – 45 years old. Two women, […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: Allergan, Medicines360

Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement

April 24, 2018 By Fink Densford

Takeda, Shire

Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from Bloomberg. The deal could come to a head as early as today, according to the report, as both companies have been working on a tentative agreement and price for the […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: Allergan, Shire, Takeda Pharmaceutical Co

Update: Allergan, Takeda spar for Shire

April 19, 2018 By Brad Perriello

Allergan, Takeda spar for Spire

Hours after Allergan (NYSE:AGN) said it was considering an acquisition of Shire (NSDQ:SHPG), the Dublin-based company announced that it does not intend to make such an offer. Reports also surfaced today that Shire rejected a $63 billion takeover offer from Takeda Pharmaceutical (TYO:4502). Reuters, which first broke the news of Allergan’s interest in Shire, citing a pair of unnamed sources, […]

Filed Under: Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Allergan, Shire, Takeda Pharmaceutical Co

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS